{"id":"doxazosin-mysylate-gits","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Dizziness"},{"rate":"10-15","effect":"Headache"},{"rate":"8-12","effect":"Fatigue"},{"rate":"7-10","effect":"Asthenia"},{"rate":"5-10","effect":"Hypotension"},{"rate":"1-2","effect":"Syncope"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Doxazosin selectively blocks alpha-1 adrenergic receptors on smooth muscle cells in the prostate, bladder neck, and blood vessels. By antagonizing these receptors, it reduces smooth muscle tone and promotes relaxation, which decreases urinary obstruction in benign prostatic hyperplasia and reduces peripheral vascular resistance to lower blood pressure. The GITS (Gastrointestinal Therapeutic System) formulation provides extended-release delivery for once-daily dosing.","oneSentence":"Doxazosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow, and also dilates blood vessels to lower blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:35:35.971Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Benign prostatic hyperplasia with lower urinary tract symptoms"},{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT00648323","phase":"PHASE4","title":"Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2003-11","conditions":"Prostate","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Doxazosin mysylate GITS","genericName":"Doxazosin mysylate GITS","companyName":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","companyId":"pfizer-s-upjohn-has-merged-with-mylan-to-form-viatris-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Doxazosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow, and also dilates blood vessels to lower blood pressure. Used for Benign prostatic hyperplasia with lower urinary tract symptoms, Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}